AC Immune SA (ACIU) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AC Immune SA, a neuroscience-focused biopharmaceutical company, has announced the appointment of Dr. Anke Post as the new Chief Medical Officer (CMO), effective September 19, 2024. Dr. Post brings a wealth of experience from her previous roles in neuroscience and drug development at companies such as Roche, Eli Lilly, and Novartis. The outgoing CMO, Dr. Nuno Mendonça, is set to depart the company to explore new professional avenues.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
